Also known as: Protagonist Therapeutics
Protagonist Therapeutics is a U.S. discovery and development biopharmaceutical company focused on peptide therapeutics. Its pipeline includes icotyde for plaque psoriasis and rusfertide for polycythemia vera, along with additional immune and metabolic programs.
Protagonist Therapeutics reported fourth quarter and full year 2025 financial results, with two NDAs submitted and multiple Phase 3 trials advancing. The company holds $646 million in cash and expects regulatory decisions in 2026.
The FDA has accepted the New Drug Application for rusfertide, a first-in-class hepcidin mimetic peptide for polycythemia vera, and granted Priority Review with a PDUFA goal date in the third quarter of 2026.
